Potential of FX06 to prevent disease progression in hospitalized non-intubated COVID-19 patients — the randomized, EU-wide, placebo-controlled, phase II study design of IXION

Authors: Jan Kloka, Benjamin Friedrichson, Stephanie Dauth, Ann Christina Foldenauer, Anita Bulczak-Schadendorf, Maria J. G. T. Vehreschild, Francisco Maio Matos, Antoni Riera-Mestre, Antoinette D. I. van Asselt, Edoardo De Robertis, Vilma Traskaite Juskeviciene, Patrick Meybohm, Dana Tomescu, Karine Lacombe, Coen D. A. Stehouwer, Kai Zacharowski, on behalf of the IXION Collaboration Group

Source: Trials, Vol 23, Iss 1, Pp 1-12 (2022)

Subject Terms: FX06, COVID-19, Disease progression, Capillary leak, Inflammation, Medicine (General), R5-920

File Description: electronic resource

Relation: https://doaj.org/toc/1745-6215

Access URL: https://doaj.org/article/3b762561ed1341cb9ed66582802669f3